Cancer vaccines: should we be targeting patients with less aggressive disease?

References

• Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64(3), 529–564 (1994).
   PubMed Web of Science ®Google Scholar
• Burnet M. Cancer; a biological approach. I. The processes of control. Br. Med. J. 1(5022), 779–786 (1957).
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3(11), 991–998 (2002).
   PubMed Web of Science ®Google Scholar
• Prestwich RJ, Errington F, Hatfield P et al. The immune system–is it relevant to cancer development, progression and treatment? Clin. Oncol. (R. Coll. Radiol). 20(2), 101–112 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203–213 (2003).
   PubMed Web of Science ®Google Scholar
• Clark WH Jr, Elder DE, Guerry D 4th et al. Model predicting survival in Stage I melanoma based on tumor progression. J. Natl Cancer Inst. 81(24), 1893–1904 (1989).
   PubMed Web of Science ®Google Scholar
• Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7), 1303–1310 (1996).
   PubMed Web of Science ®Google Scholar
• Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 74(1), 43–47 (1996).
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74(4), 1275–1282 (1994).
   PubMed Web of Science ®Google Scholar
• Marrogi AJ, Munshi A, Merogi AJ et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int. J. Cancer 74(5), 492–501 (1997).
   PubMed Web of Science ®Google Scholar
• Schumacher K, Haensch W, Röefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 61(10), 3932–3936 (2001).
   PubMed Web of Science ®Google Scholar
• Vesalainen S, Lipponen P, Talja M, Syrjänen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J. Cancer 30A(12), 1797–1803 (1994).
   PubMed Web of Science ®Google Scholar
• Sharma P, Shen Y, Wen S et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl Acad. Sci. USA 104(10), 3967–3972 (2007).
   PubMed Web of Science ®Google Scholar
• Chianese-Bullock KA, Irvin WP Jr, Petroni GR et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J. Immunother. 31(4), 420–430 (2008).
   PubMed Web of Science ®Google Scholar
• Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56(20), 4749–4757 (1996).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sherry RM, Morton KE et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175(9), 6169–6176 (2005).
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Salgaller ML, Southwood S et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157(6), 2539–2548 (1996).
   PubMed Web of Science ®Google Scholar
• Coulie PG, Karanikas V, Lurquin C et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol. Rev. 188, 33–42 (2002).
   PubMed Web of Science ®Google Scholar
• Tsioulias G, Godwin TA, Goldstein MF et al. Loss of colonic HLA antigens in familial adenomatous polyposis. Cancer Res. 52(12), 3449–3452 (1992).
   PubMed Web of Science ®Google Scholar
• Sers C, Kuner R, Falk CS et al. Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int. J. Cancer 125(7), 1626–1639 (2009).
   PubMed Web of Science ®Google Scholar
• Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F. Role of altered expression of HLA class I molecules in cancer progression. Adv. Exp. Med. Biol. 601, 123–131 (2007).
   PubMed Web of Science ®Google Scholar
• Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 20(Suppl. 4), A40–A45 (2002).
   Google Scholar
• Kantoff PW, Higano CS, Shore ND et al..; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Peoples GE, Holmes JP, Hueman MT et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 14(3), 797–803 (2008).
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Clifton GT, Holmes JP et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 118(10), 2594–2602 (2012).
   PubMed Web of Science ®Google Scholar
• Morton DL, Foshag LJ, Hoon DS et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216(4), 463–482 (1992).
   PubMed Web of Science ®Google Scholar
• Hsueh EC, Essner R, Foshag LJ et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol. 20(23), 4549–4554 (2002).
   PubMed Web of Science ®Google Scholar
• Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: canvaxin therapeutic polyvalent cancer vaccine. Semin. Cancer Biol. 13(6), 401–407 (2003).
   PubMed Web of Science ®Google Scholar
• Morton DM, Mozzillo N, Thompson J et al. An international, randomized double-blind, Phase 3 study of the specific active immunotherapy agent, onamelatucel-L (Canvaxin™), compared to placebo as a post-surgical adjuvant in AJCC Stage IV melanoma. Ann. Surg. Oncol. 13(Suppl. 5) (2006) (Abstract 21).
   Google Scholar
• Morton DL, Ollila DW, Hsueh EC, Essner R, Gupta RK. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J. Clin. 49(2), 101–16, 65 (1999).
   PubMed Web of Science ®Google Scholar
• Morton DL, Eilber FR, Joseph WL, Wood WC, Trahan E, Ketcham AS. Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann. Surg. 172(4), 740–749 (1970).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines. US Department of Health and Human Services, Silver Spring, MD, USA (2009).
   Google Scholar
• Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102(18), 1388–1397 (2010).
   PubMed Web of Science ®Google Scholar
• Curigliano G, Rescigno M, Goldhirsch A. Immunology and breast cancer: therapeutic cancer vaccines. Breast 16(Suppl. 2), S20–S26 (2007).
   PubMed Web of Science ®Google Scholar
• Miles DW, Taylor-Papadimitriou J. Mucin based breast cancer vaccines. Expert Opin. Investig. Drugs 7(11), 1865–1877 (1998).
   PubMedGoogle Scholar
• Miles D, Roché H, Martin M et al..; Theratope® Study Group. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16(8), 1092–1100 (2011).
   PubMed Web of Science ®Google Scholar
• Mayordomo JTA, Miles D, Finke L, Jenkins H. Long-term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STn-KLH vaccine with KLH control in Stage IV breast cancer following first-line chemotherapy. J Clin Oncol. 22, 2603 (2004).
   Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4(3), 321–327 (1998).
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364(22), 2119–2127 (2011).
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Theoret MR, Restifo NP. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J. Sci. Am. 6(Suppl. 1), S76–S80 (2000).
   Google Scholar
• Burch PA, Breen JK, Buckner JC et al. Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6(6), 2175–2182 (2000).
   PubMed Web of Science ®Google Scholar
• Hoover HC Jr, Brandhorst JS, Peters LC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a Phase III prospectively randomized trial. J. Clin. Oncol. 11(3), 390–399 (1993).
   PubMed Web of Science ®Google Scholar
• Kalady MF, Sanchez JA, Manilich E, Hammel J, Casey G, Church JM. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis. Colon Rectum 52(6), 1039–1045 (2009).
   PubMed Web of Science ®Google Scholar
• Harris JE, Ryan L, Hoover HC Jr et al. Adjuvant active specific immunotherapy for Stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. 18(1), 148–157 (2000).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for Stage II and Stage III human colon cancer: a randomised trial. Lancet 353(9150), 345–350 (1999).
   PubMed Web of Science ®Google Scholar
• Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of Stage II and Stage III colon cancer with an autologous tumor cell vaccine: first randomized Phase III trials show promise. Vaccine 19(17–19), 2576–2582 (2001).
   PubMed Web of Science ®Google Scholar
• Miyagawa N, Kono K, Mimura K, Omata H, Sugai H, Fujii H. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells. Oncology 70(1), 54–62 (2006).
   PubMed Web of Science ®Google Scholar
• Schultz ES, Lethé B, Cambiaso CL et al. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res. 60(22), 6272–6275 (2000).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JZM, Linder A, Dahabre J et al. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in Stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25(Suppl.), 398s (2007).
   Google Scholar
• De Plaen E, Arden K, Traversari C et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40(5), 360–369 (1994).
   PubMed Web of Science ®Google Scholar
• Marchand M, van Baren N, Weynants P et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80(2), 219–230 (1999).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JFZM, Dahabreh IJ, Linder A et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected Stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol. 26(Suppl.), 397s (2008).
   Google Scholar
• Tyagi P, Mirakhur B. MAGRIT: the largest-ever Phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin. Lung Cancer 10(5), 371–374 (2009).
   PubMed Web of Science ®Google Scholar
• Kirkwood JMDB, Hauschild A, Schadendorf D, et al. DERMA Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3- positive resected Stage III melanoma. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract TPS232).
   Google Scholar
• Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 58(21), 4902–4908 (1998).
   PubMed Web of Science ®Google Scholar
• Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5(6), 1289–1297 (1999).
   PubMed Web of Science ®Google Scholar
• Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181(6), 2109–2117 (1995).
   PubMed Web of Science ®Google Scholar
• Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96(9), 3102–3108 (2000).
   PubMed Web of Science ®Google Scholar
• Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20(11), 2624–2632 (2002).
   PubMed Web of Science ®Google Scholar
• Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin. Cancer Res. 8(5), 1014–1018 (2002).
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol. Immunother. 57(10), 1511–1521 (2008).
   PubMed Web of Science ®Google Scholar
• Murray JL, Gillogly ME, Przepiorka D et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 8(11), 3407–3418 (2002).
   PubMed Web of Science ®Google Scholar
• Vreeland TJCG, Sears AK, Hale DF et al. Long-term clinical benefit of adjuvant breast cancer vaccine: 5 year efficacy of E75 with multiple booster inoculations. Cancer Res. 71(Suppl. 24) (2011).
   Google Scholar
• Mittendorf EA, Sharma P. Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev. Vaccines 9(1), 89–105 (2010).
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182(2), 459–465 (1995).
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1(5), 405–413 (1994).
   PubMed Web of Science ®Google Scholar
• Kawamura K, Bahar R, Natsume W, Sakiyama S, Tagawa M. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors. Cancer Gene Ther. 9(1), 109–115 (2002).
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198(12), 1875–1886 (2003).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5(10), 2963–2970 (1999).
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7(10), 1118–1122 (2001).
   PubMed Web of Science ®Google Scholar
• McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J. Immunol. 163(7), 3718–3726 (1999).
   PubMed Web of Science ®Google Scholar
• Lu T, Ramakrishnan R, Altiok S et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Invest. 121(10), 4015–4029 (2011).
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24(34), 5373–5380 (2006).
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27(2), 186–192 (2009).
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Hiraoka N, Yamagami W et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res. 13(3), 902–911 (2007).
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942–949 (2004).
   PubMed Web of Science ®Google Scholar
• Wolf D, Wolf AM, Rumpold H et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11(23), 8326–8331 (2005).
   PubMed Web of Science ®Google Scholar
• Seliger B, Stoehr R, Handke D et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol. Immunother. 59(4), 529–540 (2010).
   PubMed Web of Science ®Google Scholar
• Qifeng S, Bo C, Xingtao J, Chuanliang P, Xiaogang Z. Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics. J. Thorac. Cardiovasc. Surg. 141(3), 808–814 (2011).
   PubMed Web of Science ®Google Scholar
• Yamagami W, Susumu N, Tanaka H et al. Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int. J. Gynecol. Cancer 21(9), 1628–1634 (2011).
   PubMed Web of Science ®Google Scholar
• Yuan XK, Zhao XK, Xia YC, Zhu X, Xiao P. Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J. Int. Med. Res. 39(4), 1381–1391 (2011).
   PubMed Web of Science ®Google Scholar
• Valkov A, Kilvaer TK, Sorbye SW et al. The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas. J. Transl. Med. 9, 200 (2011).
   PubMed Web of Science ®Google Scholar
• Sears AKCG, Vreeland TJ, Hale DF et al. Vaccination with the HER2-derived E75 peptide vaccine in breast cancer patients may confer greater benefit topatients with less aggressive disease. J. Immunother. 34(9), 708 (2011).
   Google Scholar
• Amin A, Benavides LC, Holmes JP et al. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol. Immunother. 57(12), 1817–1825 (2008).
   PubMed Web of Science ®Google Scholar
• Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South. Med. J. 81(9), 1109–1112 (1988).
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
   PubMed Web of Science ®Google Scholar
• Wang C, Sanders CM, Yang Q et al. High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T cell subsets. Proc. Natl Acad. Sci. USA 107(4), 1518–1523 (2010).
   PubMed Web of Science ®Google Scholar